Generic placeholder image

Current Cancer Therapy Reviews


ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Research Article

Expression of a Disintegrin and Metalloprotease 10 Gene Polymorphisms in a Cohort of Egyptian Patients with Hepatocellular Carcinoma

Author(s): Amal A. Mohamed , Dina M. Abo-Elmatty , Omnia I ezzat , Ahmed A. Youssef , Eman T. Mehanna , Alshymaa A. Hassnine , Noha M. Mesbah, Salma Saed, Eman Al Sayed , Mahmoud Hamada , Afaf F. Khamis, Ayman Elshentenawy, Marwa S.E. Abd El-Raouf, Sherief Abd-Elsalam* and Amr M. Elsayed

Volume 17 , Issue 4 , 2021

Published on: 27 April, 2021

Page: [312 - 318] Pages: 7

DOI: 10.2174/1573394717666210427122703

Price: $65


Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality. There is a need for a marker associated with HCC progression. A disintegrin and metalloprotease (ADAMs) family proteins have a lot of functions in cell adhesion, migration, proteolysis and signaling.

Aims: The aim of the study was to investigate the relation between ADAM 10 gene single nucleotide polymorphisms (SNPs) and HCC progression.

Methods: This study involved 201 cases divided: Group I (67 HCC patients), Group II (67 cirrhotic patients), Group III (67 control). Each group was subjected to laboratory investigations: (CBC, blood sugar, kidney and liver function, viral markers, alpha fetoprotein), imaging: (abdominal ultrasonography, and triphasic C.T) and ADAM 10 gene polymorphism (rs 653765, rs 383902) detection by real – time PCR.

Results: There was a statistically significant difference in the frequency and genotyping of ADAM10 SNPs in HCC patients in comparison to cirrhotic and control groups [the frequency of rs 653765 genotypes (p=0.015) and model (p=0.013)]; likewise, the frequency of rs 383902 genotypes (p<0.001) and model (p=0.001)). Also, there was a statistically significant association between different SNP rs 383902 genotype with CLIP stages (p=0.02) and with VISUM stages (p=0.035).

Conclusion: ADAM-10 is overexpressed in HCC patients and involved in HCC progress. These findings highlight that ADAM inhibitor may be used as therapeutic goals in the treatment of HCC.

Keywords: Hepatocellular carcinoma (HCC), adisintegrin and metalloprotease (ADAMs), liver cirrhosis, single nucleotide polymorphisms (SNP), HBV, HCV.

Forner A, Reig M, Varela M, et al. Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. Med Clín 2016; 146(511): e1-e22.
Mohamed AA, Ali-Eldin ZA, Elbedewy TA, El-Serafy M, Ali-Eldin FA, AbdelAziz H. MicroRNAs and clinical implications in hepatocellular carcinoma. World J Hepatol 2017; 9(23): 1001-7.
[] [PMID: 28878865]
Sukowati CH, El-Khobar KE, Ie SI, Anfuso B, Muljono DH, Tiribelli C. Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World J Gastroenterol 2016; 22(4): 1497-512.
[] [PMID: 26819517]
Omar A, Abou-Alfa GK, Khairy A, Omar H. Risk factors for developing hepatocellular carcinoma in Egypt. Linchuang Zhongliuxue Zazhi 2013; 2(4): 43.
[PMID: 25841922]
Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer 2006; 6(9): 674-87.
[] [PMID: 16929323]
Liu S, Zhang W, Liu K, Ji B, Wang G. Silencing ADAM10 inhibits the in vitro and in vivo growth of hepatocellular carcinoma cancer cells. Mol Med Rep 2015; 11(1): 597-602.
[] [PMID: 25323956]
Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: Multidomain proteins with multiple functions. Genes Dev 2003; 17(1): 7-30.
[] [PMID: 12514095]
Murphy G. The ADAMs: Signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008; 8(12): 929-41.
[] [PMID: 19005493]
Klein T, Bischoff R. Active metalloproteases of the A Disintegrin and Metalloprotease (ADAM) family: Biological function and structure. J Proteome Res 2011; 10(1): 17-33.
[] [PMID: 20849079]
Blobel CP. ADAMs: Key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005; 6(1): 32-43.
[] [PMID: 15688065]
Duffy MJ, McKiernan E, O’Donovan N, McGowan PM. Role of ADAMs in cancer formation and progression. Clin Cancer Res 2009; 15(4): 1140-4.
[] [PMID: 19228719]
Yuan S, Lei S, Wu S. ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells. Oncol Rep 2013; 30(4): 1715-22.
[] [PMID: 23912592]
Turner SL, Blair-Zajdel ME, Bunning RA. ADAMs and ADAMTSs in cancer. Br J Biomed Sci 2009; 66(2): 117-28.
[] [PMID: 19637655]
Crawford HC, Dempsey PJ, Brown G, Adam L, Moss ML. ADAM10 as a therapeutic target for cancer and inflammation. Curr Pharm Des 2009; 15(20): 2288-99.
[] [PMID: 19601831]
Prinzen C, Müller U, Endres K, Fahrenholz F, Postina R. Genomic structure and functional characterization of the human ADAM10 promoter. FASEB J 2005; 19(11): 1522-4.
[] [PMID: 15972296]
Mohamed AA, Elsaid OM, Amer EA, et al. Clinical significance of SNP (rs2596542) in histocompatibility complex class I-related gene A promoter region among hepatitis C virus related hepatocellular carcinoma cases. J Adv Res 2017; 8(4): 343-9.
[] [PMID: 28417047]
Baghdady I. Study of the risk factors for hepatocellular carcinoma: Effect of their synergism. J Am Sci 2013; 9(4): 211-7.
Helal N, Ageez A, Hirzi H, Aboushousha T. Differential GLUT1 expression in hepatocellular carcinoma and peri-malignant chronic virus c hepatitis. Int J Recent Sci Res 2017; 7(12): 14743-50.
Zhang W, Liu S, Liu K, et al. A disintegrin and metalloprotease (ADAM)10 is highly expressed in hepatocellular carcinoma and is associated with tumour progression. J Int Med Res 2014; 42(3): 611-8.
[] [PMID: 24670536]
Liu Y, Zhang W, Liu S, Liu K, Ji B, Wang Y. miR-365 targets ADAM10 and suppresses the cell growth and metastasis of hepatocellular carcinoma. Oncol Rep 2017; 37(3): 1857-64.
[] [PMID: 28184920]
Shiu J-S, Hsieh M-J, Chiou H-L, et al. Impact of ADAM10 gene polymorphisms on hepatocellular carcinoma development and clinical characteristics. Int J Med Sci 2018; 15(12): 1334-40.
[] [PMID: 30275760]
Negm O, Abou Saif S, El Gharib M, Yousef M, Abd-Elsalam S. Role of low-molecular-weight heparins in prevention of thromboembolic complication after transarterial chemoembolization in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2017; 29(3): 317-21.
[] [PMID: 27893491]
Watany M, Badawi R, Elkhalawany W, Abd-Elsalam S. Study of Dickkopf-1 (DKK-1) gene expression in hepatocellular carcinoma patients. J Clin Diagn Res 2017; 11(2): OC32-4.
[] [PMID: 28384913]
Abdelfattah AAM, Rizk F, Hawash N, Hanafy A, El-Kalla F, Abd-Elsalam S. Randomized trial of preoperative administration of oral pregabalin for postoperative analgesia in patients scheduled for radiofrequency ablation of focal lesions in the liver. Int J Hyperthermia 2018; 34(8): 1367-71.
[] [PMID: 29308685]
El-Gebaly F, Abou-Saif S, Elkadeem M, et al. Study of serum soluble programmed death ligand 1 as a prognostic factor in hepatocellular carcinoma in Egyptian patients. Curr Cancer Drug Targets 2019; 19(11): 896-905.
[] [PMID: 31538897]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy